Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases
ObjectiveRituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting…